Combining cabozantinib, nivolumab and ipilimumab in advanced hepatocellular carcinoma: does benefit outweigh toxicity?
- PMID: 38247721
- DOI: 10.21037/cco-23-106
Combining cabozantinib, nivolumab and ipilimumab in advanced hepatocellular carcinoma: does benefit outweigh toxicity?
Keywords: Hepatocellular carcinoma (HCC); cabozantinib; immunotherapy; ipilimumab; nivolumab.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical